Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study (Q36770191)
Jump to navigation
Jump to search
scientific article published on 30 July 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study |
scientific article published on 30 July 2015 |
Statements
1 reference
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study (English)
1 reference
Hagop M Kantarjian
1 reference
Jorge Cortes
1 reference
Farhad Ravandi
1 reference
Elias Jabbour
1 reference
Gianluca Gaidano
1 reference
Johan Maertens
1 reference
Stephen A Strickland
1 reference
Gail J Roboz
1 reference
Hamid Sayar
1 reference
Jeffrey E Lancet
1 reference
Norbert Vey
1 reference
Gary J Schiller
1 reference
Harry P Erba
1 reference
Arnaud Pigneux
1 reference
Heinz-August Horst
1 reference
Christian Recher
1 reference
Virginia M Klimek
1 reference
Olatoyosi Odenike
1 reference
Bayard L Powell
1 reference
Angelo-Michele Carella
1 reference
Gary Acton
1 reference
Lloyd Damon
1 reference
Ellen K Ritchie
1 reference
Michael D Craig
1 reference
Xavier Thomas
1 reference
Violaine Havelange
1 reference
Hans-Günter Derigs
1 reference
Michael Heuser
1 reference
Andrew Wei
1 reference
Donna Hogge
1 reference
Adam R Craig
1 reference
Judith A Fox
1 reference
Renee Ward
1 reference
Jennifer A Smith
1 reference
Cyrus Mehta
1 reference
Robert K Stuart
1 reference
1 reference
Identifiers
1 reference